<DOC>
	<DOC>NCT02107014</DOC>
	<brief_summary>We have found that low dose naltrexone (LDN) can substantially reduce pain associated with fibromyalgia syndrome. We believe LDN may work via novel anti-inflammatory channels. The purpose of this study is to determine if LDN lowers inflammatory markers in individuals with fibromyalgia.</brief_summary>
	<brief_title>Low Dose Naltrexone (LDN) Immune Monitoring</brief_title>
	<detailed_description />
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>Females age 1865 Meets criteria for 1990 ACR criteria for fibromyalgia Able to receive venous blood draw twice a week for 16 weeks Sufficient symptom variability during baseline report Patient completes daily report during 2 week baseline period at least 80% completion rate. Opioid use Significant psychological comorbidity that in the discretion of the investigator compromises study integrity Location prohibits travel to Stanford Blood or clotting disorder Rheumatologic or autoimmune disease Acute infection Baseline blood ESR &gt;60, CRP greater than 3.0mg/L, positive rheumatoid factor, or positive ANA Use of blood thinning medication Pregnant or currently planning to become pregnant Current use of aspirin, ibuprofen, naproxen, or other confoundingantiinflammatory medication as part of regular medication regimen. Known allergy to Naltrexone or Naloxone Currently participating in another treatmentbased research study Selfreported inability to refrain from alcohol for the duration of the study period</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>